EXEL peer analysis
Exelixis (EXEL) against its competitors: price, today's move, 1-year return and market value side by side.
EXEL and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AZN AstraZeneca | $186.41 | -0.13% | 13.20% | $289.48B |
| CRIS Curis | $0.60 | 9.39% | -97.99% | $1.46M |
| GMAB Genmab | $55.60 | -2.55% | 93.95% | $35.09B |
| HCM HUTCHMED | $13.15 | -3.24% | -10.61% | $2.29B |
| INCY Incyte | $119.20 | -0.99% | 28.74% | $24.54B |
| RIGL Rigel Pharmaceuticals | $51.31 | -0.27% | 62.27% | $958.46M |
| RVMD Revolution Medicines | $189.43 | -0.98% | 221.78% | $41.00B |
| SNDX Syndax Pharmaceuticals | $12.96 | -5.05% | -3.21% | $1.22B |
| EXEL Exelixis | $71.36 | 2.84% | 83.26% | $16.93B |
- EXEL's peers: AZN (AstraZeneca), CRIS (Curis), GMAB (Genmab), HCM (HUTCHMED), INCY (Incyte), RIGL (Rigel Pharmaceuticals), RVMD (Revolution Medicines), SNDX (Syndax Pharmaceuticals).
Updated 2026-11-02 17:54 UTC